Sample Size Requirements for Combination Treatments in Tuberculous Meningitis Trials
Author Information
Author(s): Wolbers Marcel, Heemskerk Dorothee, Chau Tran Thi Hong, Yen Nguyen Thi Bich, Caws Maxine, Farrar Jeremy, Day Jeremy
Primary Institution: Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme and Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
Hypothesis
Current anti-mycobacterial regimes are not potent enough and increasing the levels of effective anti-mycobacterial drugs in the cerebrospinal fluid will improve clinical outcome.
Conclusion
A pragmatic two-arm trial of combination therapy versus standard treatment is the preferred design for tuberculous meningitis due to the excessive sample size required for factorial designs.
Supporting Evidence
- The study found that an 8-fold increase in sample size is needed for factorial designs to achieve adequate power.
- Factorial designs may miss important interactions between treatments.
- Combination trials are more feasible in diseases with limited patient pools.
Takeaway
This study shows that testing two drugs together for treating a serious illness needs a lot more patients than just testing one drug, making it harder to do.
Methodology
The study compared the power of simple randomized trials versus factorial designs using sample size calculations based on expected mortality rates.
Potential Biases
The reliance on assumptions for sample size calculations may introduce bias if the actual treatment effects differ.
Limitations
The study assumes no interactions between treatments, which may not hold true in practice.
Participant Demographics
Patients with tuberculous meningitis.
Statistical Information
P-Value
0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website